The in vitro and in vivo experiments showed that the ATD-NPs not only can selectively targeted PSMA (−) tumor via DUP-1 mediated tumor active targeting, but also efficiently increased ROS level in cancer cell to achieve complete drug release. This evidence concerns the gene FOLH1 and neoplasm.